The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist’s Perspective
Abstract
Many antisense oligonucleotides (ASOs) from several classes of molecules are currently in drug development. Despite over 20 years of pharmaceutical research, few ASOs have been marketed due to problems with clinical efficacy or preclinical toxicologic challenges. However, a number of recent developments have renewed interest in this class including the registration of mipomersen, the advent of successful screening strategies to eliminate more toxic molecules, and new understanding of the risks of off-target nucleotide binding and mitigation of potential off-target effects. Recent advances in backbone chemistries, conjugation to other moieties, and new delivery systems have allowed better tissue penetration, enhanced intracellular targeting, and less frequent dosing, resulting in fewer toxicities. While these new developments provide invigorated interest in these platforms, a few lingering challenges and preclinical/clinical toxicity issues remain to be completely resolved, including: (1) proinflammatory effects (vasculitis/inflammatory infiltrates); (2) nephrotoxicity and hepatotoxicity unrelated to lysosomal accumulation; and (3) thrombocytopenia. Recent investigative work by several laboratories have helped elucidate mechanisms for these issues, allowing a better understanding of the clinical relevance and implications of particular toxicities. It is important for toxicologists, pathologists, and regulatory reviewers to be familiar with new developments in the ASO field and their implications, as a greater number of new types of antisense molecules undergo preclinical toxicity testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
A microRNA in a Multiple-Turnover RNAi Enzyme Complex
Hutvágner, G., & Zamore, P. D. (2002) · Science · doi:10.1126/science.1073827 · Cited by 1,674
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956
Antisense oligonucleotides: basic concepts and mechanisms.
Dias, N., & Stein, C. A. (2002) · PubMed · Cited by 948
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 632
Silencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
Scacheri, P. C., Rozenblatt-Rosen, O., Caplen, N. J., Wolfsberg, T. G., Umayam, L., Lee, J. C., Hughes, C. M., Shanmugam, K. S., Bhattacharjee, A., Meyerson, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308698100 · Cited by 613
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5633 · Cited by 520
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454
Proliferative and Nonproliferative Lesions of the Rat and Mouse Urinary System
Frazier, K. S., Seely, J. C., Hard, G. C., Betton, G., Burnett, R., Nakatsuji, S., Nishikawa, A., Durchfeld-Meyer, B., & Bube, A. (2012) · Toxicologic Pathology · doi:10.1177/0192623312438736 · Cited by 299
Self-citationCrosstalk pathways between Toll-like receptors and the complement system
Hajishengallis, G., & Lambris, J. D. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.01.002 · Cited by 275
The Role of Environmental Carcinogens, Viruses, and Genetic
Powers, A., & Carbone, M. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.4.4 · Cited by 274
Antisense oligonucleotide-based therapeutics for cancer
Dean, N. M., & Bennett, C. F. (2003) · Oncogene · doi:10.1038/sj.onc.1207231 · Cited by 234
Antisense Drug Technology: Principles, Strategies, and Applications
Szymkowski, D. E. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02123-7 · Cited by 218
Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M., Auletta, C., Levin, A. A., & Kornbrust, D. J. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36667-4 · Cited by 204
Burdick, A. D., Sciabola, S., Mantena, S. R., Hollingshead, B. D., Stanton, R., Warneke, J. A., Zeng, M., Martsen, E., Medvedev, A., Makarov, S. S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku142 · Cited by 178
Jaax, M. E., Krauel, K., Marschall, T., Brandt, S., Gansler, J., Fürll, B., Appel, B., Fischer, S., Block, S., Helm, C. A., et al. (2013) · Blood · doi:10.1182/blood-2013-01-478966 · Cited by 162
Greinacher, A., Gopinadhan, M., Günther, J.-U., Omer-Adam, M. A., Strobel, U., Warkentin, T. E., Papastavrou, G., Weitschies, W., & Helm, C. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000238350.89477.88 · Cited by 161
Cuddihy, A. R., Li, S., Tam, N. W. N., Wong, A. H., Taya, Y., Abraham, N., Bell, J. C., & Koromilas, A. E. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2475 · Cited by 159
Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides
Krieg, A. Μ. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00147-5 · Cited by 154
Henry, S. P., Beattie, G., Yeh, G., Chappel, A., Giclas, P. C., Mortari, A., Jagels, M. A., Kornbrust, D. J., & Levin, A. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00142-x · Cited by 151
Applied antisense oligonucleotide technology
Stein, C. A., & Krieg, A. Μ. (1998) · Cited by 148
Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., Kwoh, T. J., Dorr, A., & Sikic, B. I. (1999) · PubMed · Cited by 148
Antisense and siRNA as agonists of Toll-like receptors
Agrawal, S., & Kandimalla, E. R. (2004) · Nature Biotechnology · doi:10.1038/nbt1042 · Cited by 144
Antisense properties of peptide nucleic acid
Larsen, H. J., Bentin, T., & Nielsen, P. E. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00145-1 · Cited by 134
Henke, E., Perk, J., Vider, J., de Candia, P., Chin, Y., Solit, D. B., Ponomarev, V., Cartegni, L., Manova, K., Rosen, N. X., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1366 · Cited by 122
Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA
Järver, P., Coursindel, T., Andaloussi, S. E., Godfrey, C., Wood, M. J. A., & Gait, M. J. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.18 · Cited by 112
Chemical Modification Study of Antisense Gapmers
Stanton, R. V., Sciabola, S., Salatto, C. T., Weng, Y., Moshinsky, D., Little, J., Walters, E., Kreeger, J. M., DiMattia, D. A., Chen, T. X., et al. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0366 · Cited by 111
Assessing unintended hybridization-induced biological effects of oligonucleotides
Lindow, M., Vornlocher, H., Riley, D. E., Kornbrust, D. J., Burchard, J., Whiteley, L. O., Kamens, J., Thompson, J. D., Nochur, S. V., Younis, H. S., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2376 · Cited by 111
Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells
Vickers, T. A., Lima, W. F., Nichols, J. G., & Crooke, S. T. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm663 · Cited by 100
Acute Kidney Injury During Therapy With an Antisense Oligonucleotide Directed Against PCSK9
van Poelgeest, E. P., Swart, R. M., Betjes, M. G. H., Moerland, M., Weening, J. J., Tessier, Y., Hodges, M. R., Levin, A. A., & Burggraaf, J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.02.359 · Cited by 95
Cattaneo, M., & Lecchi, A. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02356.x · Cited by 91
Henry, S. P., Templin, M. V., Gillett, N. A., Rojko, J. L., & Levin, A. A. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700117 · Cited by 90
Hartmann, G., Krug, A., Waller-Fontaine, K., & Endres, S. (1996) · Molecular Medicine · doi:10.1007/bf03401902 · Cited by 89
Senn, J. J., Burel, S. A., & Henry, S. P. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084004 · Cited by 88
Geuze, H. J., Slot, J. W., Strous, G. J., & Schwartz, A. L. (1983) · PubMed · Cited by 80
Burel, S. A., Han, S.-R., Lee, H.-S., Norris, D. A., Lee, B., Machemer, T., Park, S., Zhou, T., He, G., Kim, Y., et al. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0422 · Cited by 77
Synthetic Oligonucleotides: The Development of Antisense Therapeutics
Monteith, D. K. B., & Levin, A. A. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700103 · Cited by 63
Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications
Farman, C. A., & Kornbrust, D. J. (2003) · Toxicologic Pathology · doi:10.1080/01926230390174995 · Cited by 61
Kakiuchi-Kiyota, S., Koza‐Taylor, P., Mantena, S. R., Nelms, L. F., EnayetAllah, A. E., Hollingshead, B. D., Burdick, A. D., Reed, L. A., Warneke, J. A., Whiteley, L. O., et al. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft278 · Cited by 58
Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C. S., Scicchitano, M. S., Weaver, J. L., Zabka, T. S., & Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570341 · Cited by 53
Self-citationTargeted nanoparticles enhanced flow electroporation of antisense oligonucleotides in leukemia cells
Wang, S., Zhang, X., Yu, B., Lee, R. J., & Lee, L. J. (2010) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2010.06.025 · Cited by 40
Kwoh, T. J. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-21 · Cited by 40
Controversies in the Cellular Pharmacology of Oligodeoxynucleotides
Stein, C. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.207 · Cited by 39
Toxicologic Properties of 2-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man
Henry, S. P., Kim, T., Kramer-Stickland, K., Zanardi, T. A., Fey, R. A., & Levin, A. A. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-20 · Cited by 37
CpG-ODNs induces up-regulated expression of chemokine CCL9 in mouse macrophages and microglia
Ravindran, C., Cheng, Y., & Liang, S. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.10.001 · Cited by 36
Burel, S. A., Machemer, T., Ragone, F. L., Kato, H., Cauntay, P., Greenlee, S., Salim, A., Gaarde, W. A., Hung, G., Peralta, R. Q., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193789 · Cited by 31
Toxicological evaluation of oligonucleotide therapeutics.
Marquis, J. K., & Grindel, J. M. (2000) · PubMed · Cited by 25
Richardt‐Pargmann, D., & Vollmer, J. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04971.x · Cited by 15
- Liver, Gallbladder, and Exocrine Pancreas
Sahota, P. S., Popp, J. A., Hardisty, J. F., & Gopinath, C. (2013) · CRC Press eBooks · doi:10.1201/b13783-15 · Cited by 14
Choi, S.-S., Chung, E., & Jung, Y. (2010) · The Journal of Microbiology · doi:10.1007/s12275-010-0053-6 · Cited by 13
Toxicology of Oligonucleotide Therapeutics and Understanding the Relevance of the Toxicities
Levin, A. A., & Henry, S. P. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse183 · Cited by 11
Circulating immune complexes in cynomolgus macaques.
Alexander, N. J., Clarkson, T. B., & Fulgham, D. L. (1985) · PubMed · Cited by 9
Cited by
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Täubel, J., Hauke, W., Rump, S., Viereck, J., Batkai, S., Poetzsch, J., Rode, L., Weigt, H., Genschel, C., Lorch, U., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa898 · Cited by 393
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
Shen, W., De Hoyos, C. L., Migawa, M. T., Vickers, T. A., Sun, H., Low, A., Bell, T. A., Rahdar, M., Mukhopadhyay, S., Hart, C. E., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0106-2 · Cited by 345
Safety of antisense oligonucleotide and siRNA-based therapeutics
Chi, X., Gatti, P., & Papoian, T. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.013 · Cited by 280
Metadata
- Authors
- Frazier, K. S.
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2014-11-09
- Volume
- 43
- Issue
- 1
- Pages
- 78-89
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2114775015
- Cited by
- 334
- References
- 58
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.